| scholarly article | Q13442814 |
| P50 | author | Dawn Konrad-Martin | Q115540224 |
| P2093 | author name string | Kelly M Reavis | |
| Frederick Gallun | |||
| Donald Austin | |||
| Jane S Gordon | |||
| Stephen A Fausti | |||
| Garnett McMillan | |||
| Wendy J Helt | |||
| P2860 | cites work | The meaning and use of the area under a receiver operating characteristic (ROC) curve | Q29547182 |
| Evidence for basal distortion-product otoacoustic emission components | Q30475656 | ||
| Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer | Q30486848 | ||
| Steep and shallow phase gradient distortion product otoacoustic emissions arising basal to the primary tones | Q30487899 | ||
| Influence of in situ, sound-level calibration on distortion-product otoacoustic emission variability | Q30491923 | ||
| Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea | Q33179964 | ||
| Cis-platin ototoxicity in previously noise-exposed guinea pigs | Q34196954 | ||
| Relationship between cisplatin administration and the development of ototoxicity | Q34495455 | ||
| Toxicity of platinum compounds | Q35143947 | ||
| Roadmap for developing and validating therapeutically relevant genomic classifiers | Q36250264 | ||
| Genetic variants associated with cisplatin-induced ototoxicity | Q37293994 | ||
| Health literacy, communication, and treatment decision-making in older cancer patients | Q37498800 | ||
| Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum | Q39109544 | ||
| Potentiating effects of cisplatin and ethacrynic acid in ototoxicity | Q39110232 | ||
| Portable stimulus generator for obtaining high-frequency (8-14 kHz) auditory brainstem responses | Q39239223 | ||
| Synergistic interactions of noise and other ototraumatic agents. | Q39669756 | ||
| Ototoxicity of low- and moderate-dose cisplatin | Q39861157 | ||
| Ototoxicity of chemotherapeutic agents. | Q40776815 | ||
| Audiologic monitoring for ototoxicity. | Q40776860 | ||
| Evaluation of audiometric threshold shift criteria for ototoxicity monitoring | Q41583477 | ||
| Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology | Q42436551 | ||
| Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kanamycin in the guinea pig. | Q42456754 | ||
| Ototoxicity of cis-dichlorodiammine platinum (II) in guinea pigs | Q42461144 | ||
| Cis-diamminedichloroplatinum (II) ototoxicity in the guinea pig. | Q42463568 | ||
| High-frequency hearing influences lower-frequency distortion-product otoacoustic emissions | Q42468341 | ||
| Influence of ultrahigh-frequency hearing thresholds on distortion-product otoacoustic emission levels at conventional frequencies | Q43827083 | ||
| Effects of chronic tobramycin treatment on distortion product otoacoustic emissions | Q44108347 | ||
| A system for evaluating auditory function from 8000–20 000 Hz | Q44155701 | ||
| The impact of hearing loss on quality of life in older adults | Q44976571 | ||
| Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. | Q45334457 | ||
| Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children | Q45877468 | ||
| The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study | Q46215201 | ||
| Cis-diaminedichloro platinum ototoxicity. An experimental study | Q46249091 | ||
| Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place--Resident Clinical Science Award 1998. | Q48375586 | ||
| Evoked otoacoustic emissions arise by two fundamentally different mechanisms: a taxonomy for mammalian OAEs | Q48764355 | ||
| Ototoxicity of the anticancer drug cisplatin. An experimental study | Q48968290 | ||
| Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. | Q50450143 | ||
| Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions | Q50458319 | ||
| Decreased hearing after combined modality therapy for head and neck cancer. | Q50467004 | ||
| Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. | Q50467882 | ||
| Early detection of ototoxicity using 1/6th-octave steps. | Q50481751 | ||
| Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. | Q50488839 | ||
| Sources of distortion product otoacoustic emissions revealed by suppression experiments and inverse fast Fourier transforms in normal ears. | Q50491221 | ||
| Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. | Q50493780 | ||
| An individualized, sensitive frequency range for early detection of ototoxicity. | Q50498592 | ||
| Predicting audiometric status from distortion product otoacoustic emissions using multivariate analyses. | Q50501284 | ||
| The level and growth behavior of the 2 f1-f2 distortion product otoacoustic emission and its relationship to auditory sensitivity in normal hearing and cochlear hearing loss. | Q50505193 | ||
| Histopathology of human temporal bone after cis-platinum, radiation, or both. | Q50505265 | ||
| From laboratory to clinic: a large scale study of distortion product otoacoustic emissions in ears with normal hearing and ears with hearing loss. | Q50507184 | ||
| Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. | Q50510623 | ||
| The use of cumulative distributions to determine critical values and levels of confidence for clinical distortion product otoacoustic emission measurements. | Q50513936 | ||
| Toward optimizing the clinical utility of distortion product otoacoustic emission measurements. | Q50513940 | ||
| Distortion product otoacoustic emission test of sensorineural hearing loss: performance regarding sensitivity, specificity and receiver operating characteristics. | Q50516826 | ||
| Sound calibration and distortion product otoacoustic emissions at high frequencies. | Q50522886 | ||
| Risk factors for ototoxicity due to cisplatin. | Q50525012 | ||
| A comparison of transient-evoked and distortion product otoacoustic emissions in normal-hearing and hearing-impaired subjects. | Q50527541 | ||
| Otoacoustic emissions from normal-hearing and hearing-impaired subjects: distortion product responses. | Q50530706 | ||
| Interaction of cisplatin and noise on the peripheral auditory system. | Q50548304 | ||
| High-dose cisplatin treatment: hearing loss and plasma concentrations. | Q50550212 | ||
| Reliability and validity of high-frequency (8-20 kHz) thresholds obtained on a computer-based audiometer as compared to a documented laboratory system. | Q50550356 | ||
| High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. | Q50567478 | ||
| Ototoxicity of cisplatin in gynaecological cancer patients. | Q50568908 | ||
| Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck. | Q50583012 | ||
| Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. | Q50594088 | ||
| Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. | Q50603419 | ||
| Drug-induced ototoxicity. | Q50605940 | ||
| Cisplatin: evaluation of its ototoxic potential. | Q53744914 | ||
| Acoustic distortion products in rabbit ear canal. II. Sites of origin revealed by suppression contours and pure-tone exposures | Q69399310 | ||
| Cochlear mechanics: implications of electrophysiological and acoustical observations | Q71302005 | ||
| Acute changes in cochlear potentials due to cisplatin | Q73081949 | ||
| A paradigm for class prediction using gene expression profiles | Q74577062 | ||
| Comparison between intensity and pressure as measures of sound level in the ear canal | Q77576790 | ||
| Model-checking techniques based on cumulative residuals | Q77756812 | ||
| P433 | issue | 1 | |
| P921 | main subject | ototoxicity | Q1351381 |
| P304 | page(s) | 61-74 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Ear and Hearing | Q13575058 |
| P1476 | title | Distortion-product otoacoustic emission test performance for ototoxicity monitoring | |
| P478 | volume | 32 |
| Q91625306 | A Review of Cisplatin-Associated Ototoxicity |
| Q30399519 | A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment |
| Q41322067 | ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring |
| Q28468456 | Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients |
| Q47702952 | Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions. |
| Q64966017 | C-phycocyanin from Limnothrix Species KNUA002 Alleviates Cisplatin-Induced Ototoxicity by Blocking the Mitochondrial Apoptotic Pathway in Auditory Cells. |
| Q30365226 | Cisplatin-Associated Ototoxicity: A Review for the Health Professional |
| Q41322086 | Development and validation of a cisplatin dose-ototoxicity model |
| Q92404008 | Early Diagnosis of Hearing Loss in Patients Under Methadone Maintenance Treatment |
| Q47991887 | Hearing Safety From Single- and Double-Pulse Transcranial Magnetic Stimulation in Children and Young Adults |
| Q50317372 | Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy |
| Q47244174 | Long-Term Variability of Distortion-Product Otoacoustic Emissions in Infants and Children and Its Relation to Pediatric Ototoxicity Monitoring. |
| Q27318238 | Meta-Analysis of Distortion Product Otoacoustic Emission Retest Variability for Serial Monitoring of Cochlear Function in Adults. |
| Q91625312 | Monitoring Protocols for Cochlear Toxicity |
| Q41585168 | Multivariate DPOAE metrics for identifying changes in hearing: perspectives from ototoxicity monitoring. |
| Q89716165 | Noise-induced hearing loss and its prevention: integration of data from animal models and human clinical trials |
| Q50300972 | Ototoxicity: A Challenge in Diagnosis and Treatment |
| Q41999873 | Predictors of Hearing-Aid Outcomes |
| Q27342479 | Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA) |
| Q46666190 | Research protocol: Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program |
| Q55664007 | Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis. |
Search more.